A Randomized, Double Blinded, Placebo Controlled Clinical Study to evaluate the efficacy and safety of investigational product COGNIQUE in improving the normal cognitive function in healthy volunteers. - COGNIQUE

Aurea Biolabs P Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a.Subjects aged between 18 to 40 years and in good health.
•b.Subjects not taking any drugs or medications (excluding the contraceptives)
•c.Nonsmokers
•d.Subjects must refrain from caffeine or alcohol for at least 12 hours prior to testing.

•1.Subjects using nutritional supplements for cognitive function 2 weeks prior to enrolling in study
•2.Subjects affected by Attention Deficit or other related disorders, psychiatric or neurological diseases (including aphasia, sensory, motor or visual disturbances which could affect test results) and subjects diagnosed with anxiety or depression.
•3.Subjects with mental disabilities
•4.Subjects with head injuries.
•5.Subjects with medical conditions such as diabetes, hypoglycemia, psychiatric disorders, epilepsy, gastrointestinal disorders, cancer, coagulation disorders, cardiovascular, lung, kidney, thyroid, liver diseases, excessive consumption of alcohol or substance abuse/dependence.
•6.Subjects taking Coumadin, tricyclic, antidepressants, antipsychotics, and anticonvulsants or subjects already taking medications for cognitive functioning.
•7.Subjects who are pregnant or lactating or who plan to become pregnant.

发起方

Aurea Biolabs P Ltd